 SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 GLOBE NEWSWIRE -- Zai Lab Limited NASDAQ: ZLAB; HKEX: 9688, an innovative commercial-stage biopharmaceutical company, and MacroGenics NASDAQ: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, announced today that the companies have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. 